Takeda Receives Approval to Manufacture and Market Alofisel®▼ (darvadstrocel) in Japan for Treatment of Complex Perianal Fistulas in Patients with Non-active or Mildly Active Luminal Crohn’s Disease

Takeda Receives Approval to Manufacture and Market Alofisel®▼ (darvadstrocel) in Japan for Treatment of Complex Perianal Fistulas in Patients with Non-active or Mildly Active Luminal Crohn’s Disease

September 27, 2021 – Alofisel (darvadstrocel) is the first expanded human allogeneic adipose-derived mesenchymal stem cell therapy to be approved in Japan – Alofisel provides a potential cell-mediated closure option for patients with complex perianal...